Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 1 16Phase 3 9Phase 1/2 7Phase NA 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 13Squamous Cell Carcinoma of Head and Neck 12Prostatic Neoplasms 11Neoplasms 11Breast Neoplasms 9Ovarian Neoplasms 8Lung Neoplasms 8Leukemia, Myeloid, Acute 8Recurrence 7Myasthenia Gravis 7Head and Neck Neoplasms 7Stomach Neoplasms 6Colorectal Neoplasms 6Pancreatic Neoplasms 5Oropharyngeal Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Fatigue 5Urinary Bladder Neoplasms 4Mouth Neoplasms 4Melanoma 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Cholangiocarcinoma 4Rectal Neoplasms 3Peritoneal Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Glioblastoma 3

Interventions

tislelizumab 1Paclitaxel 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Esophageal Squamous Cell Carcinoma × 90 days × Clear all
NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
90 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡